ETB (company)

Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Monday, November 13, 2023
CD38, Malignancy, PD-L1, Immunomodulatory imide drug, Neck, Bristol Myers Squibb, Research, Head, Alveolar soft part sarcoma, HIV disease progression rates, Patient, Part, ETB (company), TME, Therapy, Immunoglobulin A, Cancer, Symantec Endpoint Protection, BCMA, CMV, CPS, Biology, Pharmaceutical industry, Nursing, Vaccine, Medical imaging, Engineered wood

The net loss attributable to common shareholders for the third quarter of 2023 was $4.2 million, or $0.82 per basic share and per diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the third quarter of 2023 was $4.2 million, or $0.82 per basic share and per diluted share.
  • Revenues for the third quarter of 2023 were $6.8 million, compared to $4.2 million for the same period in 2022.
  • Total research and development expenses for the third quarter of 2023 were $7.6 million, compared with $22.0 million for the same period in 2022.
  • Total general and administrative expenses for the third quarter of 2023 were $4.3 million, compared with $5.9 million for the same period in 2022.

Molecular Templates to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 1, 2023
Lotte New York Palace Hotel, Cancer, ETB (company), Therapy, Pharmaceutical industry

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences:

Key Points: 
  • AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences:
    Location: Lotte New York Palace Hotel, New York, NJ
    The presentation link will be archived for 90 days here in the “News and Media” section of the corporate website.

Molecular Templates Announces Executive Leadership Changes

Retrieved on: 
Wednesday, August 2, 2023
Columbia University, University, René, OSI Pharmaceuticals, Therapy, Senior, Transformation/transcription domain-associated protein, BioMarin Pharmaceutical, Wharton School of the University of Pennsylvania, Biotechnology, BeiGene, Medicine, Strategic planning, Washington University in St. Louis, Bachelor of Arts in Clinical Psychology, Business administration, Hematology, Paris Descartes University, ETB (company), Wesleyan University, Regulatory affairs, Master of Business Administration, Pharmacology, Mammography, ImClone Systems, Management, Nursing, Psychology, Neuroscience, Instituto de Biologia Molecular e Celular

AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.

Key Points: 
  • AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.
  • These appointments were made to better enable Molecular Templates to execute on its clinical and corporate objectives.
  • Dr. Grace Kim joined Molecular Templates in 2022 with 20 years of experience driving investor strategy, corporate strategy, and business development.
  • These management changes will help enable us to execute efficiently in the clinic and in our corporate goals,” said Eric Poma, PhD., Chief Executive and Chief Scientific Officer of Molecular Templates.

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

Retrieved on: 
Thursday, June 1, 2023
CD38, Therapy, Doctor of Philosophy, Symantec Endpoint Protection, Overalls, Cancer, Prognosis, Patient, ETB (company), Multiple myeloma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, Pharmaceutical industry

The FDA placed the Phase I study for MT-0169 on a partial clinical hold in April 2023, based on previously disclosed asymptomatic and fully reversible cardiac adverse events (“AEs”) noted in two patients dosed at 50 mcg/kg which prompted the dose reduction to 5 mcg/kg last year.

Key Points: 
  • The FDA placed the Phase I study for MT-0169 on a partial clinical hold in April 2023, based on previously disclosed asymptomatic and fully reversible cardiac adverse events (“AEs”) noted in two patients dosed at 50 mcg/kg which prompted the dose reduction to 5 mcg/kg last year.
  • “We are pleased that the FDA has removed the partial clinical hold,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of MTEM.
  • “MT-0169 represents a novel approach to myeloma that is demonstrating good safety with early signs of potential clinical benefit, particularly in the extramedullary setting, where we have seen a stringent Complete Response in a patient who remains on study for 10 months.”
    MTEM will be focusing development of MT-0169 on extramedullary myeloma, a form of myeloma that is less responsive to current therapies and carries a worse overall prognosis.
  • Up to 20% of patients with relapsed/refractory multiple myeloma have extramedullary disease.

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Friday, December 2, 2022
Therapy, Ernest, IND, Poster, Society, Patient, Cancer, Biology, COVID-19, ETB (company), Coley's toxins, Safety, ASH, Pharmaceutical industry, Molecule

Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In-person and virtual meetings may be scheduled directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

Retrieved on: 
Wednesday, November 23, 2022
COVID-19, Conference, Doctor of Philosophy, IND, Patient, ETB, Evercore, ETB (company), Piper, Q&A, Cancer, Therapy, Biology, Coley's toxins, Safety, Pharmaceutical industry, Molecule

Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs.

Key Points: 
  • Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs.
  • One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Friday, November 4, 2022
ETB, Private Securities Litigation Reform Act, Therapy, 2021 Essex County Council election, Coley's toxins, Boston Convention and Exhibition Center, Biology, GLOBE, Safety, Webcast, IND, COVID-19, Patient, Nasdaq, Immunotherapy, The Society, Annual general meeting, Q&A, PD-L1, ETB (company), Forward-looking statement, Development, R, Technology, SEC, SITC, Convention center, Cancer, Pharmaceutical industry, Molecule

The event will be webcasted and take place 11:30am 12:30pm ET Friday, November 11, 2022, at the Boston Convention Center during SITCs 37th Annual Meeting.

Key Points: 
  • The event will be webcasted and take place 11:30am 12:30pm ET Friday, November 11, 2022, at the Boston Convention Center during SITCs 37th Annual Meeting.
  • A live Q&A session will follow the presentation.
  • Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.

Molecular Templates Announces Participation in Four Upcoming Conferences

Retrieved on: 
Wednesday, August 31, 2022
COVID-19, Cancer, Safety, IND, Morgan Stanley, Coley's toxins, SEC, Antibody-drug conjugate, GLOBE, Control, Conference, Biology, Nasdaq, Therapy, ETB (company), Private Securities Litigation Reform Act, Forward-looking statement, Patient, Pharmaceutical industry, Molecule

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, Molecular Templates or MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.

Key Points: 
  • AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, Molecular Templates or MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.
  • One-on-one meetings may be scheduled via conference representatives or directly with Molecular Templates.
  • Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Acts Safe Harbor for forward-looking statements.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs

Retrieved on: 
Monday, June 6, 2022
Large-cell lung carcinoma, DLT, Biology, Society, Coley's toxins, Safety, Forward-looking statement, CEO, Breast cancer, ASCO, Dermatitis, Nasdaq, IND, Therapy, HER2, American Society of Clinical Oncology, GLOBE, Patient, Doctor of Philosophy, Private Securities Litigation Reform Act, PD-1, COVID-19, Infrared spectroscopy correlation table, CSO, PD-L1, SEC, ETB (company), ETB, Serum, PD, NSCLC, Cancer, Pharmaceutical industry, Vaccine, Palladium, Molecule

Copies of the posters presented at ASCO can be found in the Investors section of Molecular Templates corporate website under Presentations .

Key Points: 
  • Copies of the posters presented at ASCO can be found in the Investors section of Molecular Templates corporate website under Presentations .
  • ETBs offer novel biology with the potential to drive unique clinical outcomes, even against well-explored targets, said Eric Poma, Ph.D., CEO and CSO of Molecular Templates.
  • Treatment is on-going in the 32 mcg/kg cohort with no dose-limiting toxicities (DLTs) observed to date in the third cohort.
  • Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Sarah Cannon Research Institute, Risk, MTD, HER2, Doctor of Philosophy, Neoplasm, TIGIT, Private Securities Litigation Reform Act, Coley's toxins, Nasdaq, Tumor microenvironment, Breast cancer, Capillary leak syndrome, IC50, Patient, Investment, Poster, Biology, AACR, TME, PD-1, Abstract (summary), Society, COVID-19, ETB (company), American Society of Clinical Oncology, Bristol Myers Squibb, HLA, NSCLC, PD-L1, DLT, IND, Takeda, Index (publishing), Board, Forward-looking statement, General counsel, Safety, Board of directors, ASCO, Large-cell lung carcinoma, Cardiotoxicity, CLS, Therapy, PD, Infrared spectroscopy correlation table, SEC, Dermatitis, Bone disease, Cancer, GLOBE, Regulatory T cell, ETB, Fine chemical, Pharmaceutical industry, Iron ore, Vaccine, Aluminium, Medical imaging, Molecule

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.

Key Points: 
  • AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.
  • MTEM is opening new sites for the Phase 1 study and anticipates enrollment beginning in the second quarter of 2022.
  • Revenues for the first quarter of 2022 were $8.5 million, compared to $3.2 million for the same period in 2021.
  • For more details on MTEMs financial results for the first quarter 2022, refer to Form 10Q filed with the SEC.